Trial reportThe Journal of international medical research2020
Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.
Trial report in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.JAMA oncology · 2024Pooled it
- Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer.Frontiers in oncology · 2021Pooled it
- Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone forFuture oncology (London, England) · 2021Trial
- Neoadjuvant ALK tyrosine kinase inhibitor in patients with resectable locally advanced non-small cell lung cancer harboringTranslational lung cancer research · 2026Article
- Review
- A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Review
- [Application Value of Neoadjuvant Targeted Therapy in Patients with EGFR-mutant Resectable Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Systemic Therapy for Operable NSCLC: A Review of the Literature and Discussion of Future Directions.Journal of clinical medicine · 2025Review
- Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.Current oncology (Toronto, Ont.) · 2024Review
- [Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non-Small Cell Lung Cancer.Cancer research and treatment · 2024Article
- Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non-small cell lung cancer: a retrospective controlled real-world study.Frontiers in oncology · 2024Article
- A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study.Frontiers in oncology · 2024Article
- Almonertinib as a neoadjuvant therapy for patients with a superior pulmonary sulcus tumor with activated EGFR mutation: A case report.Experimental and therapeutic medicine · 2023Article
- Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Review
- Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery · 2023Article
- Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.Pharmaceutics · 2023Review
- An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer.Frontiers in oncology · 2023Article
- Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.International journal of molecular sciences · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal neoadjuvant regimen for locally advanced resectable non-small cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly improved survival in patients with
methodThirty-one treatment-naïve Chinese patients with stage IIIA NSCLC were enrolled. Patients without
resultsAfter completing neoadjuvant treatment, 12 and 8 patients from the N-TKI and N-chemo groups underwent surgery, respectively. Our data revealed that patients who received erlotinib had a marginally better clinical objective response rate (67% vs. 19%), pathological response rate (67% vs. 38%), and overall survival (51.0 months vs. 20.9 months) compared with those who received chemotherapy. Furthermore, patients in the N-TKI group had a significantly greater reduction in tumor diameter, serum carcinoembryonic level, and maximum allelic fraction.
conclusionOur findings demonstrate that erlotinib is an effective neoadjuvant regimen in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.